This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Stuart L. Fine, MD; Barbara Hawkins, MS; Maureen Maguire, PhD
Baltimore

Arch Ophthalmol. 1984;102(11):1583.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—In response to Sabates et al,¹ who recently voiced some concerns about the Macular Photocoagulation Study (MPS),² we offer the following comments:

1. The authors stated that we did not consider time of treatment as a factor in evaluating the outcome of laser treatment. In fact, the vast majority of patients enrolled in the National Eye Institute-supported Ocular Histoplasmosis Study had newly diagnosed cases. We recognized at the outset of the trial that if laser photocoagulation were to be effective, it would be preferable to treat as early as possible. Consequently, patients with visual symptoms and a new vessel membrane who were considered eligible by the principal investigator were issued treatment assignments by telephone consultation with the MPS Coordinating Center in Baltimore.
   
2. We agree with the authors that there is no documented evidence that steroids have a role in managing patients with the ocular histoplasmosis syndrome.
   

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?